New PET tracer for prostate cancer enters human testing

NCT ID NCT07149831

Recruiting now Diagnosis Sponsor: Sinotau Pharmaceutical Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new imaging agent called Flotufolastat F-18 in 6 healthy Chinese adults. The tracer is designed to light up prostate cancer cells during PET scans. Researchers are checking how safe it is, where it goes in the body, and how much radiation it gives off. This is a first step before testing it in people with prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flotufolastat F-18 Injection
What this could lead to: If successful, this could lead to a more accurate PET imaging method for detecting prostate cancer, potentially improving diagnosis and treatment planning.
What could go wrong: This is a very early Phase I trial with only 6 healthy volunteers, not patients. It only tests safety and imaging properties, not whether it actually helps diagnose cancer better than existing methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100089, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.